Hyperphosphatemia Treatment Market, Global Outlook and Forecast 2022-2028

August 2022 | 60 pages | ID: H4C338A6B780EN
Market Monitor Global

Abstracts

Hyperphosphatemia is a serum phosphate concentration > 4.5 mg/dL (> 1.46 mmol/L). Causes include chronic kidney disease, hypoparathyroidism, and metabolic or respiratory acidosis. Clinical features may be due to accompanying hypocalcemia and include tetany. Diagnosis is by serum phosphate measurement. Treatment includes restriction of phosphate intake and administration of phosphate-binding antacids, such as calcium carbonate.

This report contains market size and forecasts of Hyperphosphatemia Treatment in Global, including the following market information:

Global Hyperphosphatemia Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Hyperphosphatemia Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Sevelamer Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hyperphosphatemia Treatment include Sanofi, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Akebia Therapeutics,Inc, Vifor Pharma Management Ltd., Lupin Limited, Ardelyx,Inc., Unicycive Therapeutics Inc. and Keryx Biopharmaceuticals and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hyperphosphatemia Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hyperphosphatemia Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Hyperphosphatemia Treatment Market Segment Percentages, by Type, 2021 (%)

• Sevelamer
• Calcium-based Phosphate Binders
• Iron-based Phosphate Binders
• Lanthanum Carbonate
• Non-phosphate Binders
• Others

Global Hyperphosphatemia Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Hyperphosphatemia Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospital Pharmacy
• Retail Pharmacy
• Online Stores
• Others

Global Hyperphosphatemia Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Hyperphosphatemia Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hyperphosphatemia Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Hyperphosphatemia Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Sanofi
• Takeda Pharmaceutical Company Limited
• Astellas Pharma Inc.
• Akebia Therapeutics,Inc
• Vifor Pharma Management Ltd.
• Lupin Limited
• Ardelyx,Inc.
• Unicycive Therapeutics Inc.
• Keryx Biopharmaceuticals
• Zeria Pharmaceutical

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Hyperphosphatemia Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Hyperphosphatemia Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL HYPERPHOSPHATEMIA TREATMENT OVERALL MARKET SIZE

2.1 Global Hyperphosphatemia Treatment Market Size: 2021 VS 2028
2.2 Global Hyperphosphatemia Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Hyperphosphatemia Treatment Players in Global Market
3.2 Top Global Hyperphosphatemia Treatment Companies Ranked by Revenue
3.3 Global Hyperphosphatemia Treatment Revenue by Companies
3.4 Top 3 and Top 5 Hyperphosphatemia Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Hyperphosphatemia Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hyperphosphatemia Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Hyperphosphatemia Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Hyperphosphatemia Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Hyperphosphatemia Treatment Market Size Markets, 2021 & 2028
  4.1.2 Sevelamer
  4.1.3 Calcium-based Phosphate Binders
  4.1.4 Iron-based Phosphate Binders
  4.1.5 Lanthanum Carbonate
  4.1.6 Non-phosphate Binders
  4.1.7 Others
4.2 By Type - Global Hyperphosphatemia Treatment Revenue & Forecasts
  4.2.1 By Type - Global Hyperphosphatemia Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Hyperphosphatemia Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Hyperphosphatemia Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Hyperphosphatemia Treatment Market Size, 2021 & 2028
  5.1.2 Hospital Pharmacy
  5.1.3 Retail Pharmacy
  5.1.4 Online Stores
  5.1.5 Others
5.2 By Application - Global Hyperphosphatemia Treatment Revenue & Forecasts
  5.2.1 By Application - Global Hyperphosphatemia Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Hyperphosphatemia Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Hyperphosphatemia Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Hyperphosphatemia Treatment Market Size, 2021 & 2028
6.2 By Region - Global Hyperphosphatemia Treatment Revenue & Forecasts
  6.2.1 By Region - Global Hyperphosphatemia Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Hyperphosphatemia Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Hyperphosphatemia Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Hyperphosphatemia Treatment Revenue, 2017-2028
  6.3.2 US Hyperphosphatemia Treatment Market Size, 2017-2028
  6.3.3 Canada Hyperphosphatemia Treatment Market Size, 2017-2028
  6.3.4 Mexico Hyperphosphatemia Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Hyperphosphatemia Treatment Revenue, 2017-2028
  6.4.2 Germany Hyperphosphatemia Treatment Market Size, 2017-2028
  6.4.3 France Hyperphosphatemia Treatment Market Size, 2017-2028
  6.4.4 U.K. Hyperphosphatemia Treatment Market Size, 2017-2028
  6.4.5 Italy Hyperphosphatemia Treatment Market Size, 2017-2028
  6.4.6 Russia Hyperphosphatemia Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Hyperphosphatemia Treatment Market Size, 2017-2028
  6.4.8 Benelux Hyperphosphatemia Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Hyperphosphatemia Treatment Revenue, 2017-2028
  6.5.2 China Hyperphosphatemia Treatment Market Size, 2017-2028
  6.5.3 Japan Hyperphosphatemia Treatment Market Size, 2017-2028
  6.5.4 South Korea Hyperphosphatemia Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Hyperphosphatemia Treatment Market Size, 2017-2028
  6.5.6 India Hyperphosphatemia Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Hyperphosphatemia Treatment Revenue, 2017-2028
  6.6.2 Brazil Hyperphosphatemia Treatment Market Size, 2017-2028
  6.6.3 Argentina Hyperphosphatemia Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Hyperphosphatemia Treatment Revenue, 2017-2028
  6.7.2 Turkey Hyperphosphatemia Treatment Market Size, 2017-2028
  6.7.3 Israel Hyperphosphatemia Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Hyperphosphatemia Treatment Market Size, 2017-2028
  6.7.5 UAE Hyperphosphatemia Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Sanofi
  7.1.1 Sanofi Corporate Summary
  7.1.2 Sanofi Business Overview
  7.1.3 Sanofi Hyperphosphatemia Treatment Major Product Offerings
  7.1.4 Sanofi Hyperphosphatemia Treatment Revenue in Global Market (2017-2022)
  7.1.5 Sanofi Key News
7.2 Takeda Pharmaceutical Company Limited
  7.2.1 Takeda Pharmaceutical Company Limited Corporate Summary
  7.2.2 Takeda Pharmaceutical Company Limited Business Overview
  7.2.3 Takeda Pharmaceutical Company Limited Hyperphosphatemia Treatment Major Product Offerings
  7.2.4 Takeda Pharmaceutical Company Limited Hyperphosphatemia Treatment Revenue in Global Market (2017-2022)
  7.2.5 Takeda Pharmaceutical Company Limited Key News
7.3 Astellas Pharma Inc.
  7.3.1 Astellas Pharma Inc. Corporate Summary
  7.3.2 Astellas Pharma Inc. Business Overview
  7.3.3 Astellas Pharma Inc. Hyperphosphatemia Treatment Major Product Offerings
  7.3.4 Astellas Pharma Inc. Hyperphosphatemia Treatment Revenue in Global Market (2017-2022)
  7.3.5 Astellas Pharma Inc. Key News
7.4 Akebia Therapeutics,Inc
  7.4.1 Akebia Therapeutics,Inc Corporate Summary
  7.4.2 Akebia Therapeutics,Inc Business Overview
  7.4.3 Akebia Therapeutics,Inc Hyperphosphatemia Treatment Major Product Offerings
  7.4.4 Akebia Therapeutics,Inc Hyperphosphatemia Treatment Revenue in Global Market (2017-2022)
  7.4.5 Akebia Therapeutics,Inc Key News
7.5 Vifor Pharma Management Ltd.
  7.5.1 Vifor Pharma Management Ltd. Corporate Summary
  7.5.2 Vifor Pharma Management Ltd. Business Overview
  7.5.3 Vifor Pharma Management Ltd. Hyperphosphatemia Treatment Major Product Offerings
  7.5.4 Vifor Pharma Management Ltd. Hyperphosphatemia Treatment Revenue in Global Market (2017-2022)
  7.5.5 Vifor Pharma Management Ltd. Key News
7.6 Lupin Limited
  7.6.1 Lupin Limited Corporate Summary
  7.6.2 Lupin Limited Business Overview
  7.6.3 Lupin Limited Hyperphosphatemia Treatment Major Product Offerings
  7.6.4 Lupin Limited Hyperphosphatemia Treatment Revenue in Global Market (2017-2022)
  7.6.5 Lupin Limited Key News
7.7 Ardelyx,Inc.
  7.7.1 Ardelyx,Inc. Corporate Summary
  7.7.2 Ardelyx,Inc. Business Overview
  7.7.3 Ardelyx,Inc. Hyperphosphatemia Treatment Major Product Offerings
  7.7.4 Ardelyx,Inc. Hyperphosphatemia Treatment Revenue in Global Market (2017-2022)
  7.7.5 Ardelyx,Inc. Key News
7.8 Unicycive Therapeutics Inc.
  7.8.1 Unicycive Therapeutics Inc. Corporate Summary
  7.8.2 Unicycive Therapeutics Inc. Business Overview
  7.8.3 Unicycive Therapeutics Inc. Hyperphosphatemia Treatment Major Product Offerings
  7.8.4 Unicycive Therapeutics Inc. Hyperphosphatemia Treatment Revenue in Global Market (2017-2022)
  7.8.5 Unicycive Therapeutics Inc. Key News
7.9 Keryx Biopharmaceuticals
  7.9.1 Keryx Biopharmaceuticals Corporate Summary
  7.9.2 Keryx Biopharmaceuticals Business Overview
  7.9.3 Keryx Biopharmaceuticals Hyperphosphatemia Treatment Major Product Offerings
  7.9.4 Keryx Biopharmaceuticals Hyperphosphatemia Treatment Revenue in Global Market (2017-2022)
  7.9.5 Keryx Biopharmaceuticals Key News
7.10 Zeria Pharmaceutical
  7.10.1 Zeria Pharmaceutical Corporate Summary
  7.10.2 Zeria Pharmaceutical Business Overview
  7.10.3 Zeria Pharmaceutical Hyperphosphatemia Treatment Major Product Offerings
  7.10.4 Zeria Pharmaceutical Hyperphosphatemia Treatment Revenue in Global Market (2017-2022)
  7.10.5 Zeria Pharmaceutical Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Hyperphosphatemia Treatment Market Opportunities & Trends in Global Market
Table 2. Hyperphosphatemia Treatment Market Drivers in Global Market
Table 3. Hyperphosphatemia Treatment Market Restraints in Global Market
Table 4. Key Players of Hyperphosphatemia Treatment in Global Market
Table 5. Top Hyperphosphatemia Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Hyperphosphatemia Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Hyperphosphatemia Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Hyperphosphatemia Treatment Product Type
Table 9. List of Global Tier 1 Hyperphosphatemia Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hyperphosphatemia Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Hyperphosphatemia Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Hyperphosphatemia Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Hyperphosphatemia Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Hyperphosphatemia Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Hyperphosphatemia Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Hyperphosphatemia Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Hyperphosphatemia Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Hyperphosphatemia Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Hyperphosphatemia Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Hyperphosphatemia Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Hyperphosphatemia Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Hyperphosphatemia Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Hyperphosphatemia Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Hyperphosphatemia Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Sanofi Corporate Summary
Table 31. Sanofi Hyperphosphatemia Treatment Product Offerings
Table 32. Sanofi Hyperphosphatemia Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Takeda Pharmaceutical Company Limited Corporate Summary
Table 34. Takeda Pharmaceutical Company Limited Hyperphosphatemia Treatment Product Offerings
Table 35. Takeda Pharmaceutical Company Limited Hyperphosphatemia Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Astellas Pharma Inc. Corporate Summary
Table 37. Astellas Pharma Inc. Hyperphosphatemia Treatment Product Offerings
Table 38. Astellas Pharma Inc. Hyperphosphatemia Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Akebia Therapeutics,Inc Corporate Summary
Table 40. Akebia Therapeutics,Inc Hyperphosphatemia Treatment Product Offerings
Table 41. Akebia Therapeutics,Inc Hyperphosphatemia Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Vifor Pharma Management Ltd. Corporate Summary
Table 43. Vifor Pharma Management Ltd. Hyperphosphatemia Treatment Product Offerings
Table 44. Vifor Pharma Management Ltd. Hyperphosphatemia Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Lupin Limited Corporate Summary
Table 46. Lupin Limited Hyperphosphatemia Treatment Product Offerings
Table 47. Lupin Limited Hyperphosphatemia Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Ardelyx,Inc. Corporate Summary
Table 49. Ardelyx,Inc. Hyperphosphatemia Treatment Product Offerings
Table 50. Ardelyx,Inc. Hyperphosphatemia Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Unicycive Therapeutics Inc. Corporate Summary
Table 52. Unicycive Therapeutics Inc. Hyperphosphatemia Treatment Product Offerings
Table 53. Unicycive Therapeutics Inc. Hyperphosphatemia Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Keryx Biopharmaceuticals Corporate Summary
Table 55. Keryx Biopharmaceuticals Hyperphosphatemia Treatment Product Offerings
Table 56. Keryx Biopharmaceuticals Hyperphosphatemia Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Zeria Pharmaceutical Corporate Summary
Table 58. Zeria Pharmaceutical Hyperphosphatemia Treatment Product Offerings
Table 59. Zeria Pharmaceutical Hyperphosphatemia Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Hyperphosphatemia Treatment Segment by Type in 2021
Figure 2. Hyperphosphatemia Treatment Segment by Application in 2021
Figure 3. Global Hyperphosphatemia Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Hyperphosphatemia Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Hyperphosphatemia Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Hyperphosphatemia Treatment Revenue in 2021
Figure 8. By Type - Global Hyperphosphatemia Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Hyperphosphatemia Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Hyperphosphatemia Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Hyperphosphatemia Treatment Revenue Market Share, 2017-2028
Figure 12. US Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Hyperphosphatemia Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Hyperphosphatemia Treatment Revenue Market Share, 2017-2028
Figure 24. China Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Hyperphosphatemia Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Hyperphosphatemia Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Hyperphosphatemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Sanofi Hyperphosphatemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Takeda Pharmaceutical Company Limited Hyperphosphatemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Astellas Pharma Inc. Hyperphosphatemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Akebia Therapeutics,Inc Hyperphosphatemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Vifor Pharma Management Ltd. Hyperphosphatemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Lupin Limited Hyperphosphatemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Ardelyx,Inc. Hyperphosphatemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Unicycive Therapeutics Inc. Hyperphosphatemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Keryx Biopharmaceuticals Hyperphosphatemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Zeria Pharmaceutical Hyperphosphatemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)